Akinyemi Oni-Orisan, PharmD, PhD
Associate Professor
Clinical Pharmacy
School of Pharmacy

His lab is currently funded to investigate genetic determinants of efficacy and safety for statin therapy in diverse populations.

Dr. Oni-Orisan teaches and mentors pharmacy students in the Discovery Projects research program including leading the inaugural Health Disparities Discovery Group.

Dr. Oni-Orisan serves as Diversity Leader for the Department of Clinical Pharmacy to champion diversity, equity and inclusion (DEI) efforts in the department.

• Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture.
  Nature genetics 2023 Kachuri L, Mak ACY, Hu D, Eng C, Huntsman S, Elhawary JR, Gupta N, Gabriel S, Xiao S, Keys KL, Oni-Orisan A, Rodríguez-Santana JR, LeNoir MA, Borrell LN, Zaitlen NA, Williams LK, Gignoux CR, Burchard …
• Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements.
  medRxiv : the preprint server for health sciences 2023 Oni-Orisan A, Lu M, Peng JA, Krauss RM, Iribarren C, Medina MW
• Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.
  Clinical pharmacology and therapeutics 2023 Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A
• Diversity in Clinical Pharmacology: A Call to Action.
  Clinical pharmacology and therapeutics 2023 Brown K, Etrouth S, Jayachandran P, Moore J, Oni-Orisan A, Vasist L, Zheng S, Zhou Z, Dresser M
• A large genome-wide association study of QT interval length utilizing electronic health records.
  Genetics 2022 Hoffmann TJ, Lu M, Oni-Orisan A, Lee C, Risch N, Iribarren C
• Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population.
  Clinical pharmacology and therapeutics 2022 Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, Krauss RM, Risch N
• Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort.
  Cardiovascular diabetology 2022 Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N
• Perceptions of Older Men Using a Mobile Health App to Monitor Lower Urinary Tract Symptoms and Tamsulosin Side Effects: Mixed Methods Study.
  JMIR human factors 2021 Wang EY, Breyer BN, Lee AW, Rios N, Oni-Orisan A, Steinman MA, Sim I, Kenfield SA, Bauer SR
• Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study.
  JMIR formative research 2021 Lee AW, Kenfield SA, Wang EY, Enriquez A, Oni-Orisan A, Steinman MA, Sim I, Breyer BN, Bauer SR
• QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System.
  Journal of the American Heart Association 2021 Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Jorgenson E, Iribarren C
• Torsade de pointes: A nested case-control study in an integrated healthcare delivery system.
  Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2021 Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Iribarren C
• Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network.
  Clinical pharmacology and therapeutics 2021 Giacomini KM, Karnes JH, Crews KR, Monte AA, Murphy WA, Oni-Orisan A, Ramsey LB, Yang JJ, Whirl-Carrillo M
• Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
  Clinical pharmacology and therapeutics 2021 Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A
• Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing.
  Clinical and translational science 2021 Oni-Orisan A, Srinivas N, Mehta K, Das JL, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA, Biomarkers and Translational Tools Community Working Group of the American Society for Clinical …
• Embracing Genetic Diversity to Improve Black Health.
  The New England journal of medicine 2021 Oni-Orisan A, Mavura Y, Banda Y, Thornton TA, Sebro R
• PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms.
  Frontiers in digital health 2020 Bauer SR, Breyer BN, Oni-Orisan A, Steinman MA, Sim I, McCulloch CE, Kenfield SA
• The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change.
  NPJ genomic medicine 2020 Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ
• Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.
  Pharmacogenetics and genomics 2019 Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA
• Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.
  Circulation. Genomic and precision medicine 2018 Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N
• Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.
  Prostaglandins & other lipid mediators 2018 Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR
• Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
  Pharmacogenomics 2018 Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T
• Validation of Electronic Health Records for the Assessment of Statin Dosing In Research.
  Journal of Clinical Lipidology 2017 Akinyemi Oni-Orisan, Thomas Hoffmann, Marisa Medina, Eric Jorgenson, Catherine Schaefer, Ronald Krauss, Carlos Iribarren, Neil Risch
• Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding.
  The Journal of clinical investigation 2017 Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP
• Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study.
  Journal of lipid research 2015 Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR
• Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?
  Cardiology in review 2014 Oni-Orisan A, Lanfear DE
• Epoxyeicosatrienoic acids and cardioprotection: the road to translation.
  Journal of molecular and cellular cardiology 2014 Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM
• Acute decompensated heart failure: evolving literature and implications for future practice.
  Pharmacotherapy 2013 Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE
• Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice.
  Prostaglandins & other lipid mediators 2012 Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR
• Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.
  American journal of physiology. Endocrinology and metabolism 2011 Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR